Oncotelic Therapeuticsincis A Clinical Stagebiopharmaceutical Company Dedicated To Developing Innovativetherapies For Oncology And Infectious Diseasesoriginally Founded In 1988 As Oxigeneinc Thecompany Has Undergoneseveral Namechangeswith Its Current Nameadopted In November 2020 Following A Merger With Oncotelic Incit Is Publicly Traded Under Theticker Otlc Thecompany Focuses On First In Class Rna Therapeutics And Small Moleculedrugsparticularly Targeting Rarepediatric Cancers And Refractory Malignancieskey Products In Its Pipelineincludeot 101An Anti Tgf I Rna Therapeutic With Applications In Both Oncology And Infectious Diseasesca4Pa Small Moleculeagent For Melanomaand Oxi450 Which Targets Acutemyeloid Leukemiaoncotelic Is Also Enhancing Its Drug Development Through Strategic Collaborationsincluding A Merger With Pointr Data Incto Integrateai Driven Data Analytics
No conferences found for this company.
| Company Name | Mateon Therapeutics Inc |
| Country |
United States
|
| Address | N/A |
| Telephone | N/A |
| N/A |
